Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle
Mandate

Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle

March 28, 2019 M&A

Vinge has advised Lantmännen in connection with its acquisition of British Tate&Lyle’s Swedish oat production operations.

The acquisition is a part of Lantmännen’s continued focus on additional processing of oats to, inter alia, the food manufacturing industry.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Karl Klackenberg and David Lundahl (M&A), partner Johan Cederblad and associate Hampus Olsson (Environmental/Permits) as well as associates Hedvig Ekdahl (Commerical Agreements), Lisa Ullman (Employment), Karolina Cohrs (Real Property) and Klara Secher (IP).
 

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026